News

Work by 3 biobehavioral scientists aims to support Parkinson’s patients

Three biobehavioral scientists at Teachers College (TC), Columbia University are working on separate collaborative efforts in exercise, speech, and swallowing among Parkinson’s patients to potentially improve quality of life for the more than 10 million people estimated globally to be living with the progressive neurodegenerative disease. In honor…

$20M gift to boost research, care at Norton Neuroscience Institute

The estate of a longtime supporter of the Norton Neuroscience Institute at Norton Healthcare has gifted the center $20 million to help expand programming and research in Parkinson’s disease and other movement disorders. The donation from the estate of Elizabeth Pahk Cressman, MD, PhD, will aid the Louisville,…

AAN 2024: Patients, care partners see improved health with cycling

Cycling indoors on a stationary bicycle for two may improve the health and well-being of people with Parkinson’s disease and their care partners, a preliminary small study at the University of South Carolina suggests. The results were presented at the annual meeting of the American Academy of Neurology, which…

AAN 2024: ND0612 improves Parkinson’s symptom control in trial

ND0612, a formation of levodopa/carbidopa administered continuously by an under-the-skin pump, led to better symptom control for people with advanced Parkinson’s disease in a Phase 3 trial, and the therapy’s efficacy and safety were consistent irrespective of patient factors like age, weight, and medication dosage. That’s according to…

AAN 2024: Motor function in rats restored with 3D cell therapy

TreeFrog Therapeutics’ investigational cell therapy restored motor function in a rat model of Parkinson’s disease, according to a recent presentation. The therapy, designed to replace the dopamine-producing nerve cells lost in Parkinson’s, involves transplanting a three-dimensional “microtissue” that contains the cells directly into the brain. Kevin Alessandri, PhD,…

AAN 2024: AskBio’s gene therapy seen to ease motor symptoms

AB-1005, an experimental gene therapy administered directly into the brain, helped ease motor symptoms in patients with moderate Parkinson’s disease, whereas it appeared to stabilize disease progression for those with mild disease in a small Phase 1 clinical trial. No serious safety issues were reported for the 11…